Home/Pipeline/Myasthenia Gravis Live CBA Panel

Myasthenia Gravis Live CBA Panel

Myasthenia Gravis

CommercialActive

Key Facts

Indication

Myasthenia Gravis

Phase

Commercial

Status

Active

Company

Neurocode

About Neurocode

Neurocode is a private, commercial-stage diagnostics company founded in 2018, specializing in advanced testing for neurological and neuroimmunological disorders. Its core offerings include a proprietary plasma p-Tau217 assay for Alzheimer's disease and an exclusive, licensed live cell-based assay for AChR antibodies in myasthenia gravis. Operating a CAP/CLIA-certified lab, the company generates revenue by providing these high-sensitivity tests to clinicians, researchers, and clinical trial sponsors. Neurocode positions itself as a leader in niche neurology diagnostics through technological exclusivity and a focused service model.

View full company profile

Therapeutic Areas

Alzheimer's Disease Neurodegenerative Disorders Myasthenia Gravis Neuroimmunological Disorders

Other Myasthenia Gravis Drugs

Drug	Company	Phase	Status
Batoclimab (HBM9161)	Harbour BioMed	Phase 3	Out-Licensed
Nipocalimab	johnson-and-johnson-innovative-medicine	Phase 3	Active
ASIT Platform	Ahead Therapeutics	Pre-clinical	Active
KYV-101 (mivocabtagene autoleucel)	Kyverna Therapeutics	Phase 2	Recruiting